Cargando…
Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients
Approval of nusinersen, an intrathecally administered antisense oligonucleotide, for the treatment of 5q-spinal muscular atrophy (SMA) marked the beginning of a new therapeutic era in neurological diseases. Changes in routine cerebrospinal fluid (CSF) parameters under nusinersen have only recently b...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996901/ https://www.ncbi.nlm.nih.gov/pubmed/33652830 http://dx.doi.org/10.3390/brainsci11030296 |
_version_ | 1783670206368841728 |
---|---|
author | Müschen, Lars Hendrik Osmanovic, Alma Binz, Camilla Jendretzky, Konstantin F. Ranxha, Gresa Bronzlik, Paul Abu-Fares, Omar Wiehler, Flavia Möhn, Nora Hümmert, Martin W. Gingele, Stefan Götz, Friedrich Stangel, Martin Skripuletz, Thomas Schreiber-Katz, Olivia Petri, Susanne |
author_facet | Müschen, Lars Hendrik Osmanovic, Alma Binz, Camilla Jendretzky, Konstantin F. Ranxha, Gresa Bronzlik, Paul Abu-Fares, Omar Wiehler, Flavia Möhn, Nora Hümmert, Martin W. Gingele, Stefan Götz, Friedrich Stangel, Martin Skripuletz, Thomas Schreiber-Katz, Olivia Petri, Susanne |
author_sort | Müschen, Lars Hendrik |
collection | PubMed |
description | Approval of nusinersen, an intrathecally administered antisense oligonucleotide, for the treatment of 5q-spinal muscular atrophy (SMA) marked the beginning of a new therapeutic era in neurological diseases. Changes in routine cerebrospinal fluid (CSF) parameters under nusinersen have only recently been described in adult SMA patients. We aimed to explore these findings in a real-world setting and to identify clinical and procedure-associated features that might impact CSF parameters. Routinely collected CSF parameters (leukocyte count, lactate, total protein, CSF/serum albumin quotient (QAlbumin), oligoclonal bands) of 28 adult SMA patients were examined for up to 22 months of nusinersen treatment. Total protein and QAlbumin values significantly increased in the first 10 months, independent of the administration procedure. By month 14, no further increases were detected. Two patients developed transient pleocytosis. In two cases, positive oligoclonal bands were found in the beginning and in four patients throughout the whole observation period. No clinical signs of inflammatory central nervous system disease were apparent. Our data confirm elevated CSF total protein and QAlbumin during nusinersen treatment. These alterations may be caused by both repeated lumbar punctures and the interval between procedures rather than by the medication itself. Generally, there were no severe alterations of CSF routine parameters. These results further underline the safety of nusinersen therapy. |
format | Online Article Text |
id | pubmed-7996901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79969012021-03-27 Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients Müschen, Lars Hendrik Osmanovic, Alma Binz, Camilla Jendretzky, Konstantin F. Ranxha, Gresa Bronzlik, Paul Abu-Fares, Omar Wiehler, Flavia Möhn, Nora Hümmert, Martin W. Gingele, Stefan Götz, Friedrich Stangel, Martin Skripuletz, Thomas Schreiber-Katz, Olivia Petri, Susanne Brain Sci Article Approval of nusinersen, an intrathecally administered antisense oligonucleotide, for the treatment of 5q-spinal muscular atrophy (SMA) marked the beginning of a new therapeutic era in neurological diseases. Changes in routine cerebrospinal fluid (CSF) parameters under nusinersen have only recently been described in adult SMA patients. We aimed to explore these findings in a real-world setting and to identify clinical and procedure-associated features that might impact CSF parameters. Routinely collected CSF parameters (leukocyte count, lactate, total protein, CSF/serum albumin quotient (QAlbumin), oligoclonal bands) of 28 adult SMA patients were examined for up to 22 months of nusinersen treatment. Total protein and QAlbumin values significantly increased in the first 10 months, independent of the administration procedure. By month 14, no further increases were detected. Two patients developed transient pleocytosis. In two cases, positive oligoclonal bands were found in the beginning and in four patients throughout the whole observation period. No clinical signs of inflammatory central nervous system disease were apparent. Our data confirm elevated CSF total protein and QAlbumin during nusinersen treatment. These alterations may be caused by both repeated lumbar punctures and the interval between procedures rather than by the medication itself. Generally, there were no severe alterations of CSF routine parameters. These results further underline the safety of nusinersen therapy. MDPI 2021-02-26 /pmc/articles/PMC7996901/ /pubmed/33652830 http://dx.doi.org/10.3390/brainsci11030296 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Müschen, Lars Hendrik Osmanovic, Alma Binz, Camilla Jendretzky, Konstantin F. Ranxha, Gresa Bronzlik, Paul Abu-Fares, Omar Wiehler, Flavia Möhn, Nora Hümmert, Martin W. Gingele, Stefan Götz, Friedrich Stangel, Martin Skripuletz, Thomas Schreiber-Katz, Olivia Petri, Susanne Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients |
title | Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients |
title_full | Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients |
title_fullStr | Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients |
title_full_unstemmed | Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients |
title_short | Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients |
title_sort | cerebrospinal fluid parameters in antisense oligonucleotide-treated adult 5q-spinal muscular atrophy patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7996901/ https://www.ncbi.nlm.nih.gov/pubmed/33652830 http://dx.doi.org/10.3390/brainsci11030296 |
work_keys_str_mv | AT muschenlarshendrik cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT osmanovicalma cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT binzcamilla cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT jendretzkykonstantinf cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT ranxhagresa cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT bronzlikpaul cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT abufaresomar cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT wiehlerflavia cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT mohnnora cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT hummertmartinw cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT gingelestefan cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT gotzfriedrich cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT stangelmartin cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT skripuletzthomas cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT schreiberkatzolivia cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients AT petrisusanne cerebrospinalfluidparametersinantisenseoligonucleotidetreatedadult5qspinalmuscularatrophypatients |